175 related articles for article (PubMed ID: 24272336)
21. MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
Kuan CT; Wakiya K; Herndon JE; Lipp ES; Pegram CN; Riggins GJ; Rasheed A; Szafranski SE; McLendon RE; Wikstrand CJ; Bigner DD
BMC Cancer; 2010 Sep; 10():468. PubMed ID: 20809959
[TBL] [Abstract][Full Text] [Related]
22. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
23. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
24. The scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells.
Tang H; Qin Y; Li J; Gong X
BMC Biol; 2011 Mar; 9():18. PubMed ID: 21418589
[TBL] [Abstract][Full Text] [Related]
25. Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins.
Shen J; Wu Y; Shi L; Liu J; Liu S; Guan Z; Yin Z
Appl Microbiol Biotechnol; 2007 Aug; 76(1):141-9. PubMed ID: 17562041
[TBL] [Abstract][Full Text] [Related]
26. Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases.
Shin JN; Park SY; Cha JH; Park JY; Lee BR; Jung SA; Lee ST; Yun CW; Seol DW; Kim TH
Exp Cell Res; 2006 Nov; 312(19):3892-8. PubMed ID: 16996498
[TBL] [Abstract][Full Text] [Related]
27. Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.
Zhang X; Zhang X; Hu S; Zheng M; Zhang J; Zhao J; Zhang X; Yan B; Jia L; Zhao J; Wu K; Yang A; Zhang R
Nucleic Acids Res; 2017 Jun; 45(10):5930-5944. PubMed ID: 28459998
[TBL] [Abstract][Full Text] [Related]
28. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
[TBL] [Abstract][Full Text] [Related]
29. Expression, purification and characterization of heterotrimeric forms of sTRAIL using a polycistronic expression vector.
Wang B; Wang Z; Yan J; Wang L; Wang Z; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
Protein Expr Purif; 2015 Nov; 115():118-24. PubMed ID: 26256060
[TBL] [Abstract][Full Text] [Related]
30. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.
de Bruyn M; Rybczynska AA; Wei Y; Schwenkert M; Fey GH; Dierckx RA; van Waarde A; Helfrich W; Bremer E
Mol Cancer; 2010 Nov; 9():301. PubMed ID: 21092273
[TBL] [Abstract][Full Text] [Related]
31. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
[TBL] [Abstract][Full Text] [Related]
32. Tetravalent antibody-scTRAIL fusion proteins with improved properties.
Seifert O; Plappert A; Fellermeier S; Siegemund M; Pfizenmaier K; Kontermann RE
Mol Cancer Ther; 2014 Jan; 13(1):101-11. PubMed ID: 24092811
[TBL] [Abstract][Full Text] [Related]
33. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
34. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.
Mühlenbeck F; Schneider P; Bodmer JL; Schwenzer R; Hauser A; Schubert G; Scheurich P; Moosmayer D; Tschopp J; Wajant H
J Biol Chem; 2000 Oct; 275(41):32208-13. PubMed ID: 10807904
[TBL] [Abstract][Full Text] [Related]
35. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.
Trebing J; El-Mesery M; Schäfer V; Weisenberger D; Siegmund D; Silence K; Wajant H
Cell Death Dis; 2014 Jan; 5(1):e1035. PubMed ID: 24481449
[TBL] [Abstract][Full Text] [Related]
36. The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.
Liu R; Ma X; Wang H; Xi Y; Qian M; Yang W; Luo D; Fan L; Xia X; Zhou J; Meng L; Wang S; Ma D; Xi L
J Mol Med (Berl); 2014 Feb; 92(2):165-75. PubMed ID: 24158182
[TBL] [Abstract][Full Text] [Related]
37. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Siegemund M; Pollak N; Seifert O; Wahl K; Hanak K; Vogel A; Nussler AK; Göttsch D; Münkel S; Bantel H; Kontermann RE; Pfizenmaier K
Cell Death Dis; 2012 Apr; 3(4):e295. PubMed ID: 22495350
[TBL] [Abstract][Full Text] [Related]
38. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.
Schneider B; Münkel S; Krippner-Heidenreich A; Grunwald I; Wels WS; Wajant H; Pfizenmaier K; Gerspach J
Cell Death Dis; 2010 Aug; 1(8):e68. PubMed ID: 21364672
[TBL] [Abstract][Full Text] [Related]
39. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
Horita H; Thorburn J; Frankel AE; Thorburn A
J Neurooncol; 2009 Nov; 95(2):175-184. PubMed ID: 19449148
[TBL] [Abstract][Full Text] [Related]
40. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
Dobson CL; Main S; Newton P; Chodorge M; Cadwallader K; Humphreys R; Albert V; Vaughan TJ; Minter RR; Edwards BM
MAbs; 2009; 1(6):552-62. PubMed ID: 20068388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
